Want to see JP:3386 full AI Analyst Report?
3386 Stock Chart & Stats
¥1190.00
¥2.00(0.18%)
At close: 4:00 PM EST
¥1190.00
¥2.00(0.18%)
Day’s Range― - ―
52-Week Range¥1,083.00 - ¥1,486.00
Previous CloseN/A
Volume2.50K
Average Volume (3M)81.79K
Market Cap
¥7.11B
Enterprise Value¥5.00B
Total Cash (Recent Filing)¥3.19B
Total Debt (Recent Filing)¥490.00M
Price to Earnings (P/E)20.1
Beta0.29
Next Earnings
Jul 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield4.57%
Share Statistics
EPS (TTM)44.38
Shares Outstanding6,048,000
10 Day Avg. Volume21,560
30 Day Avg. Volume81,793
Financial Highlights & Ratios
PEG Ratio0.70
Price to Book (P/B)0.79
Price to Sales (P/S)0.69
P/FCF Ratio20.26
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Very Low Leverage / Strong Balance SheetAn extremely low debt load relative to equity gives enduring financial flexibility. It reduces bankruptcy risk, supports spending on R&D or inventory through cycles, and enables opportunistic M&A or capital returns without straining liquidity, strengthening long-term resilience.
Rebound In Cash Generation (2025)A sharp cash-flow rebound shows the business can convert revenues into usable cash after a weak year. Sustained OCF and FCF support reinvestment in products, steady dividend policy, and balance-sheet maintenance, increasing durability of strategic initiatives over multiple quarters.
Consistent Revenue GrowthSteady top-line expansion indicates persistent demand for research reagents and services. A growing revenue base provides scale advantages, supports fixed-cost absorption, and underpins long-term investment in product lines that align with secular life-science research funding trends.
Bears Say
Material Margin CompressionSubstantially lower margins and earnings indicate structural pressure on profitability, whether from pricing, cost inflation, or product mix shifts. If persistent, this erodes return on invested capital, limits reinvestment capacity, and weakens long-term shareholder value creation.
Historic Cash-flow VolatilityWide swings in free cash flow reduce predictability for capex, dividends and strategic spending. Volatility complicates multi-year planning and raises the risk that a future downturn could force cutbacks or delay investments critical to maintaining competitive position in research markets.
Weakened Shareholder Returns / ROE DeclineA meaningful fall in ROE signals declining efficiency in converting equity into profit. Persistently low ROE can deter capital allocation to higher‑return opportunities, may pressure management to change strategy, and could limit long-term investor support absent margin recovery.
3386 FAQ
What was Cosmo Bio Co., Ltd.’s price range in the past 12 months?
Cosmo Bio Co., Ltd. lowest stock price was ¥1083.00 and its highest was ¥1486.00 in the past 12 months.
What is Cosmo Bio Co., Ltd.’s market cap?
Cosmo Bio Co., Ltd.’s market cap is ¥7.11B.
When is Cosmo Bio Co., Ltd.’s upcoming earnings report date?
Cosmo Bio Co., Ltd.’s upcoming earnings report date is Jul 30, 2026 which is in 28 days.
How were Cosmo Bio Co., Ltd.’s earnings last quarter?
Cosmo Bio Co., Ltd. released its earnings results on May 08, 2026. The company reported ¥39.22 earnings per share for the quarter, beating the consensus estimate of N/A by ¥39.22.
Is Cosmo Bio Co., Ltd. overvalued?
According to Wall Street analysts Cosmo Bio Co., Ltd.’s price is currently Overvalued.
Does Cosmo Bio Co., Ltd. pay dividends?
Cosmo Bio Co., Ltd. pays a Semiannually dividend of ¥25 which represents an annual dividend yield of 4.57%. See more information on Cosmo Bio Co., Ltd. dividends here
What is Cosmo Bio Co., Ltd.’s EPS estimate?
Cosmo Bio Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cosmo Bio Co., Ltd. have?
Cosmo Bio Co., Ltd. has 6,048,000 shares outstanding.
What happened to Cosmo Bio Co., Ltd.’s price movement after its last earnings report?
Cosmo Bio Co., Ltd. reported an EPS of ¥39.22 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 0.717%.
Which hedge fund is a major shareholder of Cosmo Bio Co., Ltd.?
Currently, no hedge funds are holding shares in JP:3386
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cosmo Bio Co., Ltd.
Cosmo Bio Company, Limited is a key player in the life science research sector, involved in the global import, export, manufacturing, marketing, and distribution of essential biotools. Their extensive product line includes biochemical reagents, specialized kits, scientific instruments, analytical software, and diagnostic products. Among their research reagents, they offer a wide spectrum such as antibodies, antigens, bioactive substances, enzymes, peptides, amino acids, various chemicals, carbohydrates, lipids, and components derived from viruses and bacteria. They also provide crucial detection reagents, cell and tissue culture systems, and gene analysis solutions. In terms of instrumentation, Cosmo Bio supplies electrophoresis apparatuses, cell culture labware, gene manipulation systems, and data analysis software. Beyond products, the company delivers valuable services like drug discovery support, custom research, and clinical diagnostics. A significant part of their operation involves the development and manufacturing of proprietary cell and cell culture products. This includes a range of specialized cells such as adipose tissue, bone, cartilage, tooth, pancreas, liver function, cardiovascular, immune, and mesenchymal stem cells, in addition to feeder cells, tumor cell lines, coating reagents, and macrophage-related products. They also produce various assay kits for measurement, staining, detection, and purification. Furthermore, they offer specialized biotechnology research equipment, including constant-temperature transport containers, aluminum block heat insulation devices, and dew condensation prevention glass plates, alongside consigned services for custom peptide synthesis and antibody production. Serving a diverse clientele of laboratories, research institutes, and life science education and testing organizations, Cosmo Bio distributes its products through its own outlets in Japan and an international network of sales agents. The company was founded in Tokyo, Japan, in 1978, where its headquarters remain.
Technical Analysis
―
Immuno-Biological Laboratories Co., Ltd.
―
Cyfuse Biomedical K.K.
―
ReproCELL Inc.
―
CellSeed Inc.
―